Breaking Finance News

ValuEngine upgraded Biocept Inc (NASDAQ:BIOC) to Sell in a report released today.

ValuEngine has upgraded Biocept Inc (NASDAQ:BIOC) to Sell in a report released on 7/6/2017.

Yesterday Biocept Inc (NASDAQ:BIOC) traded -13.73% lower at $1.38. The company’s 50-day moving average is $1.40 and its 200-day moving average is $1.68. The last stock close price is down -25.66% from the 200-day moving average, compared to the S&P 500 which has increased 0.05% over the same time. 777,933 shares of the stock were exchanged, up from an average trading volume of 540,830

See Chart Below

Biocept Inc (NASDAQ:BIOC)

Biocept Inc has a 52 week low of $0.74 and a 52 week high of $3.39 The company’s market cap is currently $0.

About Biocept Inc (NASDAQ:BIOC)

Biocept, Inc. is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company's Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample. The ctDNA technology enables mutation detection and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The Company commercializes its Target-Selector assays for a range of solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer and melanoma.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.